MetLife Investment Management’s Cabaletta Bio CABA Stock Holding History

MetLife Investment Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Buy	+66,749	New	+$220K	﹤0.01%	2397
2024 Q4	–	Sell	-27,714	Closed	-$131K	–	2820
2024 Q3	$131K	Hold	27,714	–	–	﹤0.01%	2514
2024 Q2	$207K	Buy	27,714 +9,399	+51%	+$115K	﹤0.01%	2222
2024 Q1	$312K	Hold	18,315	–	–	﹤0.01%	1938
2023 Q4	$416K	Hold	18,315	–	–	﹤0.01%	1804
2023 Q3	$279K	Buy	18,315 +4,746	+35%	+$64.9K	﹤0.01%	2002
2023 Q2	$175K	Buy	+13,569	New	+$147K	﹤0.01%	2362

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

MetLife Investment Management's CABA Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Cabaletta Bio (CABA) in Q2 2026: 66,749 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #2397 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in CABA as recently as Q3 2024.

MetLife Investment Management first reported a position in CABA in Q2 2023 and has held it in 7 quarters since. The position peaked at $416K in Q4 2023. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

MetLife Investment Management held 66,749 shares of Cabaletta Bio worth $208K as of Q2 2026.
Cabaletta Bio was a new MetLife Investment Management position in Q2 2026.
Cabaletta Bio made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2397 holding.
MetLife Investment Management first reported a position in Cabaletta Bio in Q2 2023 and has held it in 7 quarters since.
MetLife Investment Management's Cabaletta Bio position peaked at $416K in Q4 2023.
139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.